BD said its new patient comfort clinical studies surrounding its recently launched Physioject equipment shows less pain when self-injecting.
The device encompasses a pre-filled syringe with a hidden-needle. It is intended for patients suffering from chronic diseases like rheumatoid arthritis, and MS.
Patients using the Physioject scored an average of 6 on the pain scale, instead of 15 – the average for a normal pre-filled syringe.
However when asked the reason for reduced pain, Joel Cotten, European product manager of pharmaceutical systems, said the team could only guess it is psychosomatic.
He added: “The device is a non-medical device, appears more friendly, all the needles are not visible. We can guess this helps to create better comfort. Very frankly, we don’t know exactly why, but we are currently conducting more studies.”
UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.
Simon Sturge leaves Boehringer Ingelheim to head Merck's biosimilars unit, as well as the European Medicines Agency,...
All change at biopharmas this week, as we reveal the industry movers at four biologics firms. Plus,...
Changes at Novo Nordisk, Questcor, Nicox and more in this week's column.
This week's People on the Move column sees leadership appointments at two major trade bodies, as well...